Comparison
3 Methylglutaconic Aciduria Type 4 C1855126 vs 3m Syndrome 3 C3280146
Clinical comparison between 3 Methylglutaconic Aciduria Type 4 and 3M Syndrome 3 for differential diagnosis and treatment planning.
3 Methylglutaconic Aciduria Type 4 C1855126
A metabolic disorder affecting the nervous system that typically begins in childhood. Patients may experience movement difficulties, muscle stiffness, and developmental challenges. Care involves supportive therapies and symptom management.
3m Syndrome 3 C3280146
A genetic condition causing intrauterine growth restriction and postnatal short stature with distinctive facial features. Treatment focuses on growth monitoring and supportive measures.
6 comparison axes
Onset
3 Methylglutaconic Aciduria Type 4 C1855126
0-null
3m Syndrome 3 C3280146
0-0
Onset patterns differ
Severity
3 Methylglutaconic Aciduria Type 4 C1855126
severe
3m Syndrome 3 C3280146
moderate
Different severity levels
Chronic
3 Methylglutaconic Aciduria Type 4 C1855126
Chronic
3m Syndrome 3 C3280146
Chronic
Differing course
Communicable
3 Methylglutaconic Aciduria Type 4 C1855126
No
3m Syndrome 3 C3280146
No
Different transmission
Body System
3 Methylglutaconic Aciduria Type 4 C1855126
metabolic
3m Syndrome 3 C3280146
musculoskeletal
Same/different system
Category
3 Methylglutaconic Aciduria Type 4 C1855126
metabolic
3m Syndrome 3 C3280146
genetic
Different category
Bottom line
3-methylglutaconic-aciduria-type-4-C1855126 and 3m-syndrome-3-C3280146 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3 Methylglutaconic Aciduria Type 4 C1855126 | 3m Syndrome 3 C3280146 | Discriminating power |
|---|---|---|---|
| Growth pattern | Growth restriction is not described as the defining feature. | Intrauterine growth restriction and postnatal short stature are characteristic. | High |
| Neurologic findings | Movement difficulty, muscle stiffness, and developmental challenges may occur. | Distinctive facial features are described; neurologic disease is not established as typical. | High |
| Primary system | Metabolic disorder with nervous-system involvement. | Musculoskeletal and growth phenotype. | Moderate |
When to favor each condition
Choose 3 Methylglutaconic Aciduria Type 4 C1855126 when
Childhood movement or developmental concerns
This pattern fits the supplied neurologic-metabolic description better than a primary growth syndrome.
Moderate
Suspected organic acid abnormality
The name implies abnormal 3-methylglutaconic acid, but the result alone does not establish the diagnosis.
High
Severe chronic course without primordial short stature
The source classifies severity as severe and the category as metabolic.
Moderate
Choose 3m Syndrome 3 C3280146 when
Prenatal growth restriction with persistent short stature
This matches the defining growth phenotype in the source.
High
Distinctive facial features with musculoskeletal concern
The source emphasizes facial features and the musculoskeletal system.
Moderate
Evaluation for a genetic growth syndrome
The category is genetic, with growth monitoring and supportive care described.
Moderate
How key tests differ
| Test | 3 Methylglutaconic Aciduria Type 4 C1855126 | 3m Syndrome 3 C3280146 | Interpretation |
|---|---|---|---|
| Urine organic acids | May show elevated 3-methylglutaconic acid; no cutoff is established here. | Not described as the defining test. | An abnormal metabolite supports metabolic evaluation but is not a standalone diagnosis. |
| Growth assessment | Not the primary discriminator in the source. | Prenatal and postnatal growth measurements are central. | Growth charts require clinician interpretation and exclusion of other causes. |
| Genetic testing | Molecular cause is not specified and may be heterogeneous. | A genetic condition, but a specific gene should not be assumed from this summary. | Test selection and variant interpretation require specialist judgment. |
Prognosis comparison
3 Methylglutaconic Aciduria Type 4 C1855126
- Outcome
- Chronic and potentially severe neurologic course; exact outcomes are not established.
- Factors
- Symptom severity, developmental involvement, and response to supportive care.
3m Syndrome 3 C3280146
- Outcome
- Chronic moderate growth disorder; mortality and adult outcomes are not established.
- Factors
- Degree of growth restriction, associated features, and supportive management.
Time frame: From prenatal or childhood onset into long-term follow-up; precise timelines are unavailable.
Individual variation, comorbidities, and access to specialist care.
Complications comparison
| Complication | Presentation |
|---|---|
| Developmental impairment | Developmental challenges may occur. Not established as a core feature in the source. Individual developmental course is variable and not quantified here. |
| Motor limitation | Movement difficulty and stiffness may affect function. Motor disease is not described; stature may affect some activities. Functional impact differs, and exact disability rates are unavailable. |
| Persistent short stature | Not described as the defining complication. Postnatal short stature follows intrauterine growth restriction. Other endocrine and nutritional causes still require clinical exclusion. |
Patient education highlights
- HighResult versus diagnosis
An abnormal metabolite or growth measurement needs clinician interpretation and does not by itself confirm either condition.
- HighCare focus
Left emphasizes supportive neurologic and symptom care; right emphasizes growth monitoring and supportive measures. No treatment doses are established here.
- MediumGenetic counseling
Both may have genetic implications, but inheritance details are not established in this summary.